Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 omicron virus
- Development stage
- Phase 1
- Lead developer
- hVIVO
- Administration
- Intranasal
01
Overview
SARS-CoV-2 omicron virus, specifically the BA.5 challenge strain, is a characterized viral isolate used in human challenge clinical trials to evaluate the efficacy of vaccines and therapeutics. Developed by hVIVO, this strain is administered to healthy, previously vaccinated or infected volunteers in a controlled environment to study the pathogenicity, viral shedding kinetics, and immune response to the Omicron variant. These studies are designed to establish a standardized model for testing next-generation medical countermeasures against specific variants of concern. The BA.5 lineage is characterized by multiple mutations in the spike protein that enhance immune evasion and transmissibility compared to earlier SARS-CoV-2 variants.
- Other names
- SARS-CoV-2 Omicron (BA.5) challenge strainOmicron BA.5 challenge agent
02
Targets
ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on SARS-CoV-2 omicron virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 omicron virus.